El papel de los cannabinoides en los trastornos del neurodesarrollo de niños y adolescentes
Open Access
- 1 October 2022
- journal article
- research article
- Published by IMR Press in Revista De Neurologia
- Vol. 75 (07) , 189-197
Abstract
Introduction. Neurodevelopmental disorders have a multifactorial etiology that results from the interaction between biological and environmental factors. The biological basis of many of these disorders is only partially understood, which makes therapeutic interventions, especially pharmacological ones, particularly difficult. The impact of medical cannabis on neurological and psychiatric disorders has been studied for a long time. This study aimed to review the currently available clinical and pre-clinical studies regarding the use of cannabinoids in pediatric neurodevelopmental disorders and to draw attention to the potential therapeutic role of cannabidiol in this field. Development. Cannabidiol is an endocannabinoid system modulator and exerts its effects on both developing and mature brains through numerous mechanisms. Cannabidiol holds a relatively high toxicity limit and current literature suggests that it may have anxiolytic, antipsychotic, and neuroprotective properties. Clinical evidence suggests that early treatment with cannabidiol might be a promising therapy for neurodevelopmental disorders, including intellectual disability, autism spectrum disorders, tics, and attention/deficit hyperactivity disorder. Conclusions. This review hopefully draws attention to an emerging body of evidence concerning cannabidiol's significant potential to safely improve many of the common symptoms affecting children and adolescents with neurodevelopmental disorders, especially autism spectrum disorder.Keywords
This publication has 24 references indexed in Scilit:
- Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the LiteratureCannabis & Cannabinoid Research, 2019
- Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and EfficacyScientific Reports, 2019
- Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbiditiesFrontiers in Pharmacology, 2019
- Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility StudyJournal of Autism and Developmental Disorders, 2018
- Neurodevelopmental outcome in 22q11.2 deletion syndrome and managementAmerican Journal of Medical Genetics Part A, 2018
- Neurodevelopmental disorders: prevalence and comorbidity in children referred to mental health servicesNordic Journal of Psychiatry, 2018
- ADHD in children and young people: prevalence, care pathways, and service provisionThe Lancet Psychiatry, 2018
- Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trialEuropean Neuropsychopharmacology, 2017
- Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette SyndromeThe Journal of Clinical Psychiatry, 2003
- Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover TrialPharmacopsychiatry, 2002